2010
During the U.S. healthcare deliberations, the words invention, technology, diagnostics, and wellness were mentioned rarely, if ever. No one said “revolution in healthcare” and yet a healthcare revolution is underway. Never before could a physician peer into the body, blood, or DNA of a patient and “see” the risk of disease for that person or “see” a disease at such an early stage that intervention might be crucial. That vision defines personalized medicine, which includes actionable measurements of genotype and phenotype – DNA and proteins.
For the inaugural symposium, Gold Lab invited medical and scientific thought leaders and stakeholders to debate and inform each other and the audience on how best to facilitate the most timely transformation of medicine. “Our motivation is simple,” said Dr. Larry Gold, Professor, MCDB, University of Colorado and CEO of SomaLogic, “Scientists are responsible for innovations; scientists also must participate in discussions that enable the timely use of those innovations. An informed citizenry is at the heart of an improved healthcare system.”
Larry Gold serves as the Founder and Chairman of the Board of SomaLogic, and is a Professor at the University of Colorado Boulder.
Dr. Richard A. Spritz is Professor of Pediatrics and Director of the Human Medical Genetics Program at the University of Colorado School of Medicine.
William N. Rom M.D., MPH is the Sol and Judith Professor of Medicine and Environmental Medicine at New York University School of Medicine and Director of the Division of Pulmonary and Critical Care Medicine.
Dr. Williams trained as a physician at Charing Cross and Westminster medical school, University of London, and following his internships returned to the same institution for a Ph.D. in medicine and physiology.
Fintan Steele joined SomaLogic in 2011 as executive director for communications. Fintan's background includes more than 20 years of experience in communicating scientific research, particular the science (and its implications) behind the "omics revolution."
Dr. George Poste is Chief Scientist, Complex Adaptive Systems Initiative (CASI) at Arizona State University. This program links expertise across the university in research on synthetic biology, ubiquitous sensing and Healthcare informatics for personalized medicine.
Dr. Wohlgemuth is Vice President of Science & Innovation of the Quest Diagnostics Nichols Institute in San Juan Capistrano, CA.
Donald Jones serves as vice president of business development for Qualcomm Incorporated. He is responsible for leading Qualcomm’s expansion of wireless technologies into the consumer health, healthcare and medical device markets.
As Medco’s Chairman and Chief Executive Officer, David B. Snow, Jr., architected the transformation of Medco Health Solutions into an enterprise that is today recognized as one of the world’s most admired and innovative companies, and a leader in clinically driven pharmacy care that empowers the practice of precision medicine.
Dr. Cech was raised and educated in Iowa (B.A. in chemistry from Grinnell College, 1970). He obtained his Ph.D. in chemistry from the University of California, Berkeley.
Scott Danielson is a tinkerer, inventor and entrepreneur who creates high-impact, high-value, customer-centered products and services.
Larry is an expert in biotechnology, a field that he has worked in commercially for over 27 years. In 1981, he was a founding scientist of Genetics Institute (acquired by Wyeth), one of the earliest biotechnology companies.
Pat Furlong is the Founding President and CEO of Parent Project Muscular Dystrophy (PPMD), the largest non profit organization in the United States solely focused on Duchenne muscular dystrophy (Duchenne).
Keith Gottesdiener, M.D., is Chief Executive Officer of Rhythm Pharmaceuticals, Inc., a Boston based biotech company that specializes in the development of peptide therapeutics for the treatment of metabolic diseases, such as diabetes, obesity and functional GI disorders.
Denver. Richard D. Lamm is one of the new breed of policy analysts who argues that the challenge of the 21st century is to meet new public needs by reconceptualizing much of what government does and how it does it.
Daniel Kracov is a Partner and Head of the FDA and Healthcare Regulatory Practice Group at Arnold & Porter LLP.
David Rosenman is a hospital-based physician at the Mayo Clinic in Rochester, Minnesota. At the Mayo Medical School, David's pride and joy is the Preclinical Block, a six-week, multidisciplinary transition from the classroom to the real world
Dr. Lawrence served as CEO and Chairman of Kaiser Foundation Health Plan and Hospitals until his retirement in 2002. He was appointed CEO in 1991 and Chairman the next year.
Larry Gold serves as the Founder and Chairman of the Board of SomaLogic, and is a Professor at the University of Colorado Boulder.
Has been canceled due to the coronavirus pandemic.
Please join us next year, May 14-15, 2021